Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Heyward J, Lesko CR, Murray JC, Mehta HB, et al. JAMA Oncol 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.

Read + Share

Amedeo Smart

Independent Medical Education

Heyward J, Lesko CR, Murray JC, Mehta HB, et al. Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. JAMA Oncol 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.
PMID: 40338588